Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
about
The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment ResponseConsiderations and challenges in defining optimal iron utilization in hemodialysisCurrent and potential imaging applications of ferumoxytol for magnetic resonance imaging.Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a feasibility study in children.Accelerated ferumoxytol-enhanced 4D multiphase, steady-state imaging with contrast enhancement (MUSIC) cardiovascular MRI: validation in pediatric congenital heart disease.Nanoparticle enhanced MRI scanning to detect cellular inflammation in experimental chronic renal allograft rejection.Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.In vivo tracking of human adipose-derived stem cells labeled with ferumoxytol in rats with middle cerebral artery occlusion by magnetic resonance imaging.Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterialsComparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patientsSafety and technique of ferumoxytol administration for MRI.MRI with ferumoxytol: A single center experience of safety across the age spectrumIntravenous Ferumoxytol in Pediatric Patients With Iron Deficiency Anemia.Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia.The available intravenous iron formulations: History, efficacy, and toxicology.Gadolinium-based contrast agents in pediatric magnetic resonance imaging.When should we use contrast material in cardiac MRI?Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits.Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients.Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.Ten Things You Might Not Know about Iron Oxide Nanoparticles.Crossover comparison of ferumoxytol and gadobenate dimeglumine for abdominal MR-angiography at 3.0 tesla: Effects of contrast bolus length and flip angle.Intravenous Irons: From Basic Science to Clinical PracticeThe biocompatibility evaluation of iron oxide nanoparticles synthesized by a one pot process for intravenous iron supply
P2860
Q26773129-5D85F561-B0F0-4F26-B0BF-7311E9AFBB5CQ28088564-89CE7693-639F-43BC-A65A-A028514A44ABQ30234702-F27D3F60-AD7C-4140-B974-28A8B384D461Q30367692-E3906CE1-B0B1-4652-BF22-26D57DBC0ECDQ30395371-EF194B5A-EFC1-4888-8384-6FB9A9F1DE95Q35543722-22977530-5D1F-419A-8DC2-7359CE5642B3Q35656127-807524FF-AEDD-4A40-81FA-93A0CE17AF0FQ35837970-3759031E-62BC-49D7-8637-3DED4CD9A9F1Q36263980-04EFF8F7-CDC2-4604-B7D9-D764106BA4DAQ36287535-F0A9310E-6662-4FA6-BECC-009C7A9A4322Q36790975-F5B7C436-5B15-4E37-B4D8-9A12666C429AQ36862859-DEA437A0-92A6-440B-8C58-9F1CD3312DF0Q37622520-0F797605-1BF4-4255-8438-BBAC3EBDCBAAQ38722040-47CF6E23-CF53-45D1-85A1-6B5467F32FD6Q38966351-54A6C5FF-8E2D-44C9-BA88-12AFBA9E3A4DQ39216462-68B79E76-1C55-48ED-9B9A-4794F3E950E2Q39242162-10846BD9-7D28-494F-B878-C0B4DCBB5043Q39290073-76EFE2EA-A4A3-4222-85FD-2F80A05D64C3Q46071655-74DE6F71-4E75-47BA-838C-8228EFE61400Q47102798-3B88D22C-715C-4389-98A4-867EE80C9ECBQ47137741-F781A90D-789F-4CEE-94EA-F8C28DA107EAQ47199588-F0CCCD46-294E-4342-A7A9-797D08C8483AQ47367815-19ADDEC2-257D-41D3-AB04-851F4B99B0D9Q48146534-D21B5296-5A8F-4916-B7DF-2F839A29AF26Q48215270-F7A8EBD9-21F5-4687-B762-8675CF697DE4Q57167424-4D0F2D92-7DF2-4ED6-B03F-A938F539A4C7Q57238642-632C3E9B-7499-48E7-A7DB-484CB965F195
P2860
Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Safety and effectiveness of fe ...... States over a 12-month period.
@en
Safety and effectiveness of fe ...... States over a 12-month period.
@nl
type
label
Safety and effectiveness of fe ...... States over a 12-month period.
@en
Safety and effectiveness of fe ...... States over a 12-month period.
@nl
prefLabel
Safety and effectiveness of fe ...... States over a 12-month period.
@en
Safety and effectiveness of fe ...... States over a 12-month period.
@nl
P2093
P1476
Safety and effectiveness of fe ...... States over a 12-month period.
@en
P2093
Amit Sharma
Brigitte Schiller
Premila Bhat
P356
10.1016/J.CLINTHERA.2013.09.028
P577
2013-12-07T00:00:00Z